SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioventix Regulatory News (BVXP)

Share Price Information for Bioventix (BVXP)

Share Price is delayed by 15 minutes
Get Live Data
1,625.00    75.00 (4.84%)
Bid:
1,600.00
Ask:
1,650.00
Spread: 50.00 (3.125%)
Market Cap: £84.90m
BVXP Live PriceLast checked at - London Stock Exchange

Intraday Bioventix Share Chart

Director/PDMR Shareholding

31 Jan 2023 17:03

RNS Number : 4761O
BioVentix PLC
31 January 2023
 

Bioventix plc

("Bioventix" or the "Company")

 

Director/PDMR Shareholdings and Issue of Equity

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the following Directors have dealt in the Company's ordinary shares of 5 pence each (the "Ordinary Shares"):

 

Director

Role

Options over Ordinary Shares exercised

Ordinary Shares sold

Sale price per Ordinary Share

Ordinary Shares held on Admission

% of issued share capital held on Admission

Ian Nicholson

Non-Executive Chairman

1,600

1,600

3,750

15,500

0.3%

Peter Harrison

Chief Executive Officer

-

57,588

3,750

359,088

6.9%

Nicholas McCooke

Non-Executive Director

2,752

2,752

3,750

-

-

 

The options over Ordinary Shares ("Options") were exercised at a price of 1350 pence per Ordinary Share pursuant to the Company's 2013 EMI Share Option Scheme, details of which can be found at www.bioventix.com. In addition, a current employee exercised 2,000 Options.

 

Issue of Equity

 

The Company has applied for 6,352 new Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur and that dealings will commence in the new Ordinary Shares on 6 February 2023. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

The total number of Ordinary Shares in issue following Admission will be 5,215,685 and the Company holds no shares in treasury. Therefore, the total number of Ordinary Shares with voting rights in the Company will be 5,215,685.

 

The above figure of 5,215,685 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Bioventix under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further information please contact:

Bioventix plc

Peter Harrison

Bruce Hiscock

 

Chief Executive Officer

Chief Financial Officer

Tel: 01252 728 001

finnCap Ltd

Geoff Nash/Simon Hicks

Alice Lane

 

Corporate Finance

ECM

Tel: 020 7220 0500

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Ian Nicholson

2.

Reason for the Notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Exercise of Options over Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1,350p

1,600

d)

Aggregated information:

· Aggregated volume

· Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

Off market transaction

 

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Ian Nicholson

2.

Reason for the Notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

3,750

1,600

d)

Aggregated information:

· Aggregated volume

· Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Peter Harrison

2.

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

3,750p

57,558

d)

Aggregated information:

· Aggregated volume

· Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Nicholas McCooke

2.

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Exercise of Options over Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1,350p

2,752

d)

Aggregated information:

· Aggregated volume

· Price

 

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

Off market transaction

 

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Nicholas McCooke

2.

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

3,750p

2,752

d)

Aggregated information:

· Aggregated volume

· Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAXFFDEEDEFA
Date   Source Headline
3rd May 201911:03 amPRNHolding(s) in Company
1st May 20193:32 pmPRNHolding(s) in Company
5th Apr 20199:46 amPRNIssue of Equity
29th Mar 20197:00 amPRNHalf-year Report
14th Mar 20192:51 pmPRNHolding(s) in Company
29th Jan 20197:00 amPRNIssue of Equity
17th Jan 20195:07 pmPRNHolding(s) in Company
17th Jan 20195:07 pmPRNHolding(s) in Company
17th Jan 20195:07 pmPRNHolding(s) in Company
6th Dec 20183:46 pmPRNResult of AGM
5th Dec 20182:33 pmPRNHolding(s) in Company
5th Dec 20182:24 pmPRNHolding(s) in Company
8th Oct 20187:00 amPRNResults for the year ended 30 June 2018
3rd Sep 20188:44 amPRNNotice of Results and Notice of AGM
28th Aug 20182:22 pmPRNIssue of Equity
29th Jun 20185:25 pmPRNHolding(s) in Company
4th May 20183:15 pmPRNHolding(s) in Company
12th Apr 201811:38 amPRNHolding(s) in Company
26th Mar 20187:00 amPRNHalf-year Report
13th Feb 201810:29 amPRNHolding(s) in Company
18th Dec 20174:04 pmPRNResult of AGM
20th Oct 201710:09 amPRNDirector/PDMR Shareholding
20th Oct 20179:48 amPRNHolding(s) in Company
16th Oct 20177:00 amPRNFinal Results
20th Sep 201711:21 amPRNHolding(s) in Company
4th Sep 20177:00 amPRNTrading Update, Notice of Results & AGM
14th Aug 201710:06 amPRNHolding(s) in Company
7th Aug 201711:45 amPRNHolding(s) in Company
10th May 20179:00 amPRNSiemens Launches New Troponin Test
10th Apr 201711:18 amPRNHolding(s) in Company
3rd Apr 201712:14 pmPRNHolding(s) in Company
30th Mar 201711:21 amPRNIssue of Equity
27th Mar 20177:00 amPRNInterim Results
13th Jan 20173:55 pmPRNHolding(s) in Company
5th Jan 201711:43 amPRNHolding(s) in Company
7th Dec 20165:43 pmPRNResult of AGM
18th Nov 20166:01 pmPRNDirector/PDMR Shareholding
14th Nov 201611:47 amPRNNotice of AGM
17th Oct 20167:00 amPRNFinal Results
10th Oct 20162:05 pmRNSSecond Price Monitoring Extn
10th Oct 20162:00 pmRNSSecond Price Monitoring Extn
10th Oct 201611:00 amRNSPrice Monitoring Extension
22nd Aug 20167:00 amPRNTrading Update and Notice of Results
8th Aug 20168:18 amPRNHolding(s) in Company
14th Jul 20169:10 amPRNIssue of Equity
3rd Jun 201611:09 amPRNHolding(s) in Company
31st May 20167:00 amPRNCollaboration with Pre Diagnostics AS
24th Mar 20165:01 pmPRNHolding(s) in Company
21st Mar 20167:00 amPRNHalf-yearly Report
14th Jan 20167:00 amPRNInvestment in CardiNor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.